

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

Recombinant Anti-TGF beta Receptor II antibody [EPR14673]

RRID:AB_2818975

Type: Antibody

Proper Citation

Abcam Cat# ab184948, RRID:AB_2818975

Antibody Information

URL: http://antibodyregistry.org/AB_2818975

Proper Citation: Abcam Cat# ab184948, RRID:AB_2818975

Target Antigen: TGFBR2

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB

Antibody Name: Recombinant Anti-TGF beta Receptor II antibody [EPR14673]

Description: This recombinant targets TGFBR2

Target Organism: human

Clone ID: EPR14673

Antibody ID: AB_2818975

Vendor: Abcam

Catalog Number: ab184948

Record Creation Time: 20231110T032545+0000

Record Last Update: 20260829T132206+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-TGF beta Receptor II antibody [EPR14673].

No alerts have been found for Recombinant Anti-TGF beta Receptor II antibody [EPR14673].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang S, et al. (2026) A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. *Neuron*.

Ling J, et al. (2025) Artificial intelligence-driven discovery of YH395A: A novel TGF β R1 inhibitor with potent anti-tumor activity against triple-negative breast cancer. *Cell communication and signaling : CCS*, 23(1), 326.

Hanada K, et al. (2024) Reduced lung metastasis in endothelial cell-specific transforming growth factor β type II receptor-deficient mice with decreased CD44 expression. *iScience*, 27(12), 111502.

Chen AP, et al. (2024) An improved approach to generate IL-15 $^{+/-}$ /TGF β R2 $^{-/-}$ iPSC-derived natural killer cells using TALEN. *Cell reports methods*, 4(9), 100857.

Carcamo S, et al. (2022) Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. *Cell reports*, 39(1), 110637.

Sun L, et al. (2022) PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF- β receptor I versus II. *Cell reports*, 38(6), 110349.

Hart PC, et al. (2019) Mesothelial Cell HIF1 β Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. *Cell reports*, 29(12), 4086.